Thank you for subscribing!
Next Investors Jun 07, 2024
Our biotech Investment, Arovella Therapeutics (ASX: ALA) is developing an iNKT cell therapy platform to fight cancer, and is setting the stage for a Phase 1 clinical trial. Basically ALA’s treatment can find, identify and kill specific cancer cells, leaving other healthy cells unharmed,
Next Investors Mar 26, 2024
Our Investment ALA is trialling a technology to find, target and attack ONLY cancer cells, leaving the rest of the body healthy and unimpacted.
Next Investors Oct 12, 2023
Our preclinical biotech Investment, Arovella Therapeutics (ASX: ALA) has just announced that its cancer fighting cell-therapy may now also be able to more effectively target pancreatic, gastric and lung cancer.
Next Investors Apr 17, 2023
This morning Arovella Therapeutics (ASX: ALA) released new data indicating its treatment, ALA-101, has the potential to be a novel, ‘off the shelf’ cell therapy to treat leukemias and lymphomas.
Get expert stock analysis direct in your inbox
Next Investors Oct 28, 2022
Arovella Therapeutics (ASX:ALA) announced on Wednesday that it had decided to phase out its legacy operations to fully focus on its CAR iNKT treatment for cancer.
Next Investors Sep 27, 2022
Yesterday, Arovella Therapeutics (ASX:ALA) announced that it had signed a partnership agreement with $1.1BN capped Imugene to develop its technology to target solid tumour cancer cells.
Finfeed Sep 02, 2022
Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment in DXB is currently sitting below that price at 14.5 cents.
Finfeed Archived May 12, 2020
PharmAust (ASX: PAA) has released promising data in relation to its monepantel canine trial, investigating the anti-cancer effects of monepantel tablets in dogs.
Finfeed Archived Feb 27, 2020
The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.
Finfeed Archived Jan 08, 2020
PharmAust Limited’s (ASX:PAA) wholly-owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases initiative.
Finfeed Archived Dec 16, 2019
Australian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to the Telethon Kids Institute.
Finfeed Archived Dec 11, 2019
PharmAust Ltd (ASX:PAA), a clinical-stage oncology company that’s developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.
Finfeed Archived Nov 28, 2019
Shares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage oncology company developing personalised medicine approaches to cancer released promising news.
Finfeed Archived Nov 18, 2019
With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.
Finfeed Archived Nov 13, 2019
Imagion Biosystems Limited (ASX:IBX) has been issued patent #320872 from the Government of India Patent Office.
Next Investors Archived Nov 07, 2019
One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.
Finfeed Archived Nov 04, 2019
Clinical stage oncology company, PharmAust Ltd (ASX:PAA) has provided recruitment guidance for its anti-cancer trialling goals with treatment naïve B cell lymphoma.
Finfeed Archived Nov 01, 2019
Clinical-stage oncology company, PharmAust (ASX:PAA) has released its quarterly, highlighting the company's recent successes.
Join Our Mailing List
